Case D C
Oncology. 1984;41(3):159-63. doi: 10.1159/000225814.
58 consecutively referred, previously untreated patients with nodular lymphomas (stages III and IV) were treated with two different combination chemotherapy regimens-(cyclophosphamide, vincristine and prednisone (COP), and BCNU , cyclophosphamide, vincristine, melphalan and prednisone (M-2) - to compare remission induction and duration as well as survival. The two groups were comparable for age, stage IV and histology. The complete response for each combination was greater than 80%. Median duration of remission for the COP-treated patients is 18 months. Remission duration and survival are superior for M-2-treated patients. The difference in remission duration and survival advantage is statistically significant for the M-2 protocol compared with COP at 5 years (p less than 0.01).
58例连续转诊、既往未经治疗的结节性淋巴瘤患者(III期和IV期)接受了两种不同的联合化疗方案——环磷酰胺、长春新碱和泼尼松(COP),以及卡莫司汀、环磷酰胺、长春新碱、美法仑和泼尼松(M-2)——以比较缓解诱导、缓解持续时间以及生存率。两组在年龄、IV期和组织学方面具有可比性。每种联合方案的完全缓解率均超过80%。接受COP治疗的患者的中位缓解持续时间为18个月。接受M-2治疗的患者的缓解持续时间和生存率更高。与COP方案相比,M-2方案在5年时的缓解持续时间差异和生存优势具有统计学意义(p<0.01)。